Valganciclovir上市了吗？

On August 20, 2006, Shanghai Roche Pharmaceutical Co., Ltd. held a press conference for the launch of valganciclovir hydrochloride tablets () in China in Dalian. The meeting invited clinical and pharmacological experts from Roche's headquarters and well-known scholars in my country's transplant community to give speeches. It also invited reporters and editors from many domestic newspapers and medical professional media. More than 200 clinicians from the transplant community from across the country attended the meeting.

Cytomegalovirus infection is a common complication after organ transplantation, with an incidence rate as high as 50%. The pain caused by organ rejection, cardiovascular disease, post-transplantation diabetes and related treatments has seriously affected the quality of life of patients. Valganciclovir Hydrochloride Tablets (Valganciclovir) is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. Just taking 2 tablets of Valganciclovir Hydrochloride Tablets (Valganciclovir) every day can effectively prevent and treat CMV infection, avoid the direct and indirect harm caused by CMV infection, and significantly improve the patient's quality of life and long-term survival rate.

Professor Tang Xiaoda, chairman of the Chinese Dialysis and Transplantation Research Association, told reporters: "Patients should not only focus on before surgery, but also on how to maintain the survival of transplanted organs and improve overall quality of life after surgery. In particular, prevention of cytomegalovirus infection in patients at risk should be given sufficient attention."

So far, Valganciclovir Hydrochloride Tablets (Valganciclovir) are on the market in major countries around the world. By collecting price data of Valganciclovir Hydrochloride Tablets (Valganciclovir) in different countries, we will find that the price of Valganciclovir Hydrochloride Tablets (Valganciclovir) in the "World Pharmacy" India is the lowest.